Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has issued a positive reimbursement recommendation for SKYRIZI® (risankizumab) for adults with moderately to severely active ulcerative colitis, while AbbVie has simultaneously finalized a Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) to advance public-payer access
Science Significance
The AMC recommendation is strongly supported by robust Phase III clinical evidence, particularly the INSPIRE and COMMAND trials for ulcerative colitis and earlier pivotal programs for Crohn’s disease, including MOTIVATE, ADVANCE, and FORTIF. The therapy’s mechanism—selective inhibition of interleukin-23 (IL-23)—targets a cytokine deeply involved in intestinal inflammation, reinforcing the scientific momentum behind IL-23–directed monoclonal antibodies in immune-mediated diseases. The press materials emphasize that SKYRIZI is a humanized monoclonal antibody, validated across multiple inflammatory conditions such as psoriasis, psoriatic arthritis, Crohn’s disease, and now ulcerative colitis. This consistent efficacy profile strengthens the scientific rationale for shared pathways across autoimmune pathologies.
Regulatory Significance
The AMC’s conditional public reimbursement recommendation marks a significant regulatory milestone in Canada’s evolving framework for precision biologics. The recommendation incorporates feedback from 25 clinicians and two national patient organizations, ensuring that real-world needs and clinical relevance guided the final decision Additionally, AbbVie’s completed Letter of Intent with the pCPA signals completion of key national price-negotiation steps—often one of the largest hurdles to public formulary adoption. The alignment across agencies further illustrates Canada’s maturing coordination between regulatory, clinical-evidence, and health-technology–assessment processes.
Business Significance
Advertisement
For AbbVie, SKYRIZI represents a flagship immunology asset, and expanding its label into ulcerative colitis solidifies the product’s strategic position within the company’s post-Humira portfolio. The AMC decision, combined with the pCPA agreement, strengthens AbbVie’s competitive stance against other biologics and emerging oral therapies targeting JAK inhibition. AbbVie leaders highlighted their collaboration with national health authorities, underlining a deliberate strategy to secure reimbursement pathways across diverse therapeutic areas. With an estimated 120,000 Canadians currently living with ulcerative colitis, the commercial impact is significant, especially within a market characterized by long-term therapy use
Patients’ Significance
Patients with ulcerative colitis often face debilitating symptoms such as persistent diarrhea, abdominal pain, and rectal bleeding, which deeply affect quality of life. SKYRIZI offers a new therapeutic route for individuals who have not responded adequately to conventional therapy, prior biologics, or JAK inhibitor. Patient organizations have recognized the decision as providing “greater hope” and addressing an urgent need for personalized, effective, and durable treatment. By integrating patient voices directly into reimbursement reviews, this decision aligns clinical benefits with lived experience—an increasingly crucial component of modern healthcare assessment.
Policy Significance
The dual milestone—AMC recommendation and pCPA pricing alignment—illustrates how Canada’s policy frameworks are adapting to the growing complexity of biologics and the rising prevalence of IBD nationwide. With inflammatory conditions placing substantial pressure on public-health budgets, the incorporation of real-world feedback while maintaining cost-containment measures provides a template for future biologic evaluations. The process demonstrates a shift toward collaborative, multi-stakeholder decision-making, where regulators, clinicians, patient groups, and manufacturers collectively influence national access policies. This may accelerate access to other next-generation immunomodulators and help standardize reimbursement timelines across provinces.
The AMC’s positive recommendation for SKYRIZI, supported by strong Phase III data and a decisive pricing agreement with the pCPA, marks a major advancement for inflammatory bowel disease management in Canada. With its targeted IL-23 mechanism and expanding clinical portfolio, SKYRIZI stands poised to reshape therapeutic options for thousands of Canadians living with ulcerative colitis. As patient groups, clinicians, and regulators continue advocating for equitable biologic access, this milestone underscores the transformative potential of science-backed policy coordination in improving chronic-disease care nationwide.
Source: AbbVie press release
